XpresCheck™ Shatters the Time Barrier in Airport COVID-19 Testing
24 August 2020 - 11:00PM
XpresSpa Group, Inc. (Nasdaq: XSPA), a health and wellness company,
has made a major stride in advancing airport COVID-19 testing by
slashing the waiting time for results from 48 hours or more to
under 15 minutes. The Company has signed a contract with Abbott
Laboratories securing 100 ID NOW testing instruments. This rapid
molecular testing technology has emerged as a critical part of the
diagnostic landscape to help fight the pandemic by allowing fast,
accurate diagnosis.
Dr. Marcelo Venegas, Medical Officer, said,
“Cutting the time for results to 15 minutes or less changes the
testing paradigm for travelers and airport employees, creating a
series of benefits. It means early detection results are known in
time to take appropriate measures to prevent disease transmission.
This is literally a shortcut to a safer environment for airport
staff, travelers, and all of the communities in which they
come in contact.”
Securing the use of the Abbott devices is part
of XpresCheck’s strategy to deliver transformative testing and
healthcare services to airports across the country. This first
mover advantage in the airport space will roll out in September at
its flagship locations in JFK International Airport and Newark
Liberty International Airport.
Doug Satzman, XpresSpa Group CEO, said, “These
point-of-care tests are critical to enhancing early detection
because of their portability, speed, and reliability which can
accelerate care, reduce viral spread, and help people get on the
road to recovery sooner. We’ve already identified 60 Large Hub and
Medium Hub airports and are in advanced discussions to open
additional locations. Our expansion plan includes offering a range
of appropriate services and treatments too. We are proud to be
playing our part in supporting the return of air travel to
pre-pandemic levels by making sure both airport employees and
travelers feel safe and confident when they come to the
airport.”
The ID NOW COVID-19 has not been FDA cleared or
approved. It has been authorized by the FDA under an emergency use
authorization for use by authorized laboratories and patient care
settings. The test has been authorized only for the detection of
nucleic acid from SARS-CoV-2, not for any other viruses or
pathogens, and is only authorized for the duration of the
declaration that circumstances exist justifying the authorization
of emergency use of in vitro diagnostic tests for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C.
§ 360bbb-3(b)(1), unless the authorization is terminated or revoked
sooner.
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a global health and wellness
holding company. XpresSpa Group’s core asset, XpresSpa, is a
leading airport retailer of spa services and related health and
wellness products, with 50 locations in 25 airports globally.
Through its XpresTest, Inc. subsidiary, the Company also provides
COVID-19 screening and testing under its XpresCheck™ brand at JFK
International Airport and Newark Liberty International Airport. To
learn more about XpresSpa Group, visit: www.XpresSpaGroup.com. To
learn more about XpresSpa, visit www.XpresSpa.com. To learn more
about XpresCheck, visit www.XpresCheck.com.
Forward-Looking Statements This
press release may contain "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. These include
statements preceded by, followed by or that otherwise include the
words "believes," "expects," "anticipates," "estimates,"
"projects," "intends," "should," "seeks," "future," "continue," or
the negative of such terms, or other comparable terminology. In
particular, these statements include, without limitation,
statements about our future operating or financial performance,
market opportunity and growth strategy, in particular statements
about our expectations relating to our new XpresCheck™ concept, our
ability to identify and convert spa locations to XpresCheck™ sites
on a timely and cost-efficient basis, being able to expand testing
to other communicable diseases as well as administer vaccinations
for the seasonal flu, our positioning to be part of the national
rollout of a COVID-19 vaccination when it becomes available
(including whether such vaccination becomes available in the near
term or at all), the degree to which our public testing model
assists passengers meet testing requirements in select states and
countries, our ability to identify and gain access to the latest
and best COVID-19 testing methodologies and equipment, and our
ability expand our initial sites at JFK International Airport and
Newark Liberty International Airport as we currently expect, and
our overall ability to manage the regulatory challenges associated
with this business line. Forward-looking statements relating to
expectations about future results or events are based upon
information available to XpresSpa Group as of today's date and are
not guarantees of the future performance of the company, and actual
results may vary materially from the results and expectations
discussed. Additional information concerning these and other risks
is contained in XpresSpa Group’s most recently filed Annual Report
on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports
on Form 8-K and other Securities and Exchange Commission filings.
All subsequent written and oral forward-looking statements
concerning XpresSpa Group, or other matters and attributable to
XpresSpa Group or any person acting on its behalf are expressly
qualified in their entirety by the cautionary statements above.
XpresSpa Group does not undertake any obligation to publicly update
any of these forward-looking statements to reflect events or
circumstances that may arise after the date hereof.
Investor Relations: Raphael
Gross, ICR ir@xpresspagroup.com
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From Apr 2024 to May 2024
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From May 2023 to May 2024